Ariproct

Ariproct is a topical/rectal combination product indicated for the short-term symptomatic relief of anorectal conditions. Its principal uses are:

• Internal and external hemorrhoids (piles): established use for relief of pain, itching, burning, swelling, and discomfort, including where secondary bacterial infection is present or likely.
• Anal fissures and pruritus ani (anal itching): symptomatic relief of associated pain and irritation.
• Post-hemorrhoidectomy and post-anorectal-surgical care: adjunct short-term symptom relief as directed by a physician.
• Proctitis and other minor inflammatory anorectal conditions with an associated risk of secondary bacterial infection.

Ariproct is intended for short-term symptomatic use only; it does not treat the underlying cause of hemorrhoidal disease and is not a substitute for definitive medical or surgical management when indicated.

Cinchocaine + Hydrocortisone + Neomycin + Esculin is a fixed-dose combination for topical/rectal use. Representative composition (exact strengths may vary slightly by manufacturer and dosage form; confirm on the product label):

• Cinchocaine hydrochloride - a local anesthetic, typically around 0.5% w/w
• Hydrocortisone (as acetate) - a topical corticosteroid, typically around 0.5-1% w/w
• Neomycin (as sulfate) - a topical aminoglycoside antibiotic, providing an equivalent unit-dose amount per gram/suppository
• Esculin (esculoside/aescin) - a plant-derived venotonic and vascular-protective agent, typically around 1% w/w

It is available as a rectal ointment/cream (for external and lower-internal application) and as suppositories (for internal/rectal use).

Ariproct is a multi-action topical/rectal preparation combining a local anesthetic, a corticosteroid, a topical antibiotic, and a vascular-protective agent in a single formulation. It is used for the short-term relief of pain, itching, inflammation, and swelling associated with hemorrhoids and other anorectal disorders, while also providing antibacterial cover and support for local venous/capillary tone.

This combination is typically supplied as a rectal ointment and as suppositories, applied directly to the affected area or inserted into the rectum as directed by a physician.

Anorectal (anti-hemorrhoidal) combination preparation containing a local anesthetic, a corticosteroid, a topical antibiotic, and a venotonic/vascular-protective agent. Ariproct belongs to this combination therapeutic class.

Cinchocaine + Hydrocortisone + Neomycin + Esculin combines four active components, each contributing a distinct pharmacological action:

• Cinchocaine is an amide-type local anesthetic that reversibly blocks voltage-gated sodium channels in nerve membranes, preventing initiation and conduction of nerve impulses, which relieves local pain, burning, and itching.
• Hydrocortisone is a corticosteroid with local anti-inflammatory, antipruritic, and vasoconstrictive actions, reducing inflammatory mediator release, capillary permeability, and local edema.
• Neomycin is an aminoglycoside antibiotic that binds the bacterial 30S ribosomal subunit, inhibiting protein synthesis and providing local antibacterial cover against susceptible organisms, reducing the risk of secondary infection in inflamed or excoriated tissue.
• Esculin (esculoside), derived from horse chestnut, is a venotonic/vascular-protective agent thought to reduce capillary fragility and permeability and support venous tone, helping to reduce local congestion and edema.

Systemic absorption after correct topical/rectal application is generally low, but can increase with prolonged use, application to broken or extensively inflamed mucosa, or use of occlusive dressings.

Apply Ariproct ointment externally to the perianal area, or internally using the applicator provided, after gently cleaning and drying the area. Insert suppositories into the rectum, preferably after a bowel movement. Wash hands before and after application, avoid contact with the eyes, and do not use occlusive dressings unless directed by a physician.

Clinically significant interactions with Ariproct are uncommon when used as directed, given generally low systemic absorption, but the following should be noted:

• Other local anesthetics: concurrent use of additional topical or systemic local anesthetics may increase the risk of additive local anesthetic toxicity.
• Other ototoxic/nephrotoxic drugs (e.g. systemic aminoglycosides): concomitant use could theoretically increase risk if significant systemic absorption of the neomycin component occurs, such as with prolonged use on broken or extensively inflamed mucosa.
• Other topical or systemic corticosteroids: concurrent extensive use of other corticosteroid-containing products may increase the risk of systemic corticosteroid effects, particularly in children or with prolonged use.

Inform your physician or pharmacist about all other medicines and topical products being used before starting Ariproct.

Most adverse effects with Ariproct are local and mild, especially with short-term use:

• Common: local burning, stinging, or itching sensation on application; local irritation.
• Less common: allergic contact dermatitis or hypersensitivity reactions, particularly related to the neomycin component, which carries a relatively high rate of contact sensitization with prolonged use.
• With prolonged/excessive use: skin or mucosal thinning (atrophy), telangiectasia, and rarely, systemic corticosteroid effects (e.g. adrenal suppression) or signs of neomycin-related ototoxicity/nephrotoxicity if significant systemic absorption occurs.

Stop use of Ariproct and consult a physician if signs of hypersensitivity (rash, swelling, severe irritation) occur.

Pregnancy: There are limited controlled data on the use of Ariproct in pregnancy. It should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus, for the shortest effective duration; consult a physician before use. Use in the first trimester and prolonged or extensive use should be avoided unless directed by a physician.

Lactation: It is not established whether clinically significant amounts of the components of Ariproct are excreted in breast milk after topical/rectal use. Caution is advised; consult a physician before use while breastfeeding, particularly for prolonged use.

Ariproct is intended for short-term use only. Precautions include:

• Duration of use: avoid continuous or prolonged use; re-evaluate with a physician if symptoms do not improve within about 7 days, or if rectal bleeding, severe pain, or other new symptoms develop, to exclude other causes such as fissure, infection, or anorectal malignancy.
• Skin/mucosal atrophy: prolonged use of the corticosteroid component may cause local atrophy, thinning, or telangiectasia of the skin/mucosa.
• Sensitization: the neomycin component carries a recognized risk of contact sensitization with prolonged or repeated use; discontinue if signs of allergic reaction develop.
• Infection masking: the corticosteroid component may mask signs of infection or allow a pre-existing infection to worsen; do not use on untreated infected lesions.
• Systemic absorption: avoid use on broken, ulcerated, or extensively inflamed mucosa, and avoid occlusive dressings, as these increase systemic absorption of hydrocortisone and neomycin.
• Avoid contact with the eyes.
• Not for long-term or prophylactic use without medical supervision.
• Antibiotic stewardship: take Ariproct exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice, given its antibiotic (neomycin) component.

Overdose with topically/rectally applied Ariproct is unlikely with normal use, but excessive or prolonged application may increase systemic absorption and the associated risk of effects such as systemic corticosteroid effects or, rarely, neomycin-related ototoxicity or nephrotoxicity. In case of accidental oral ingestion or suspected overdose, seek immediate medical attention or contact a poison control center/emergency services; do not attempt unsupervised home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not freeze.

Children: safety and efficacy of Ariproct in infants and young children have not been well established; use is generally not recommended in this age group due to an increased risk of systemic absorption of the corticosteroid and antibiotic components through more permeable mucosa/skin. If use is considered necessary in an older child or adolescent, it should be under close medical supervision, for the shortest possible duration.

Elderly: no specific dose adjustment is generally required; use as directed, with attention to skin/mucosal integrity.

Renal/Hepatic impairment: no well-established dose adjustment is required for topical/rectal use, as systemic absorption is normally minimal; caution is nonetheless advised with prolonged use, particularly in significant renal impairment, given the theoretical risk of neomycin accumulation if absorbed.

Treatment with Ariproct should generally be limited to short courses, typically not exceeding about 7 days, unless otherwise directed by a physician. Continuous or repeated long-term use is not recommended because of the risks of local atrophy, sensitization, and systemic absorption associated with the corticosteroid and antibiotic components. If symptoms persist or recur after a course of treatment, medical reassessment is advised.

Combination anorectal preparation comprising: a local anesthetic (amide type - cinchocaine), a corticosteroid (glucocorticoid - hydrocortisone), a topical antibiotic (aminoglycoside - neomycin), and a venotonic/vascular-protective agent (esculin). Cinchocaine + Hydrocortisone + Neomycin + Esculin is classified as an anti-hemorrhoidal combination product.

In Cinchocaine + Hydrocortisone + Neomycin + Esculin, cinchocaine blocks voltage-gated sodium channels in sensory nerve fibers, inhibiting pain-signal transmission for local anesthesia. Hydrocortisone binds intracellular glucocorticoid receptors, suppressing inflammatory mediator synthesis and reducing local inflammation, edema, and itching. Neomycin inhibits bacterial protein synthesis by binding the 30S ribosomal subunit, providing local antibacterial action against susceptible organisms. Esculin acts on vascular endothelium and connective tissue to reduce capillary permeability and fragility and support venous tone, reducing local congestion. Together, these mechanisms provide combined anesthetic, anti-inflammatory, antibacterial, and vascular-protective effects for anorectal symptom relief.

The safety and efficacy of Ariproct in children, particularly infants and young children, have not been well established. Use in this population is generally not recommended because of a higher risk of systemic absorption of the corticosteroid and antibiotic components through thinner, more permeable skin/mucosa, which could increase the risk of systemic corticosteroid effects or neomycin-related toxicity. If a physician considers use necessary in an older child or adolescent, it should be for the shortest possible duration, under close medical supervision, and only when the potential benefit outweighs the risk.